Copyright
©The Author(s) 2019.
World J Gastroenterol. Aug 21, 2019; 25(31): 4360-4382
Published online Aug 21, 2019. doi: 10.3748/wjg.v25.i31.4360
Published online Aug 21, 2019. doi: 10.3748/wjg.v25.i31.4360
First author, year | Patients (patients) | Treatment | PVTT Class (Vp) | Median survival time(mo) | 1-yr survival rate | 2-yr survival rate | 3-yr survival rate | 5-yr survival rate |
Okazaki M, 1991 | 163 | TACE | Vp 2 (48) Vp 3 (56) Vp 4 (59) | 4.3 mo 4 mo 3.8 mo | - | - | - | - |
Chung JW, 1995 | 83 | TACE | Vp 3,4 (83) | 6 mo | 30% | 18% | 9% | - |
Georgiades CS, 2005 | 32 | TACE | Vp 3,4 (32) | 9.5 mo | 25% | - | - | - |
Luo J, 2011 | 84 | TACE | Vp 1,2 (40) Vp 3 (44) | 10.2 mo 5.3 mo | 30.9% 3.8% | 9.2% 0% | - | - |
Niu ZJ, 2012 | 115 | TACE | Vp 1 (12) Vp 2 (52) Vp 3 (42) Vp 4 (9) | 19 11 7.1 4 | 27.8% | 6% | - | - |
Peng ZW, 2012 | 402 | TACE | Vp 1 (54) Vp 2 (136) Vp 3 (166) Vp 4 (46) | - | 41.1% 37.9% 36.1% 30.4% | - | 8.9% 6% 4.2% 4.3% | 3.6% 0% 0% 0% |
Ajit Y, 2014 | TACE | 6.2 mo | - | 22% | - | - | ||
Liu L, 2014 | 188 | TACE | Vp 1,2 (98) Vp 3 (90) | 6 | 38% | 17% | 3% | - |
Liu PH, 2014 | 181 | TACE | Vp 1,2 (181) | - | 60% | - | 42% | 33% |
Chern MC, 2014 | 50 | TACE | Vp 1,2,3,4 | 6.2 mo (range, 1.7–50.9 mo) | 22% | 10% | 8% | - |
Tawada A, 2014 | 81 | TACE | Vp 1,2,3,4 | NA | 45% | 23% | 20% | - |
Ye JZ, 2014 | 338 | TACE (86 patients) | Vp 1,2,3,4 | 7.0 mo | 17.5% | 0% | 0% | - |
Tan X, 2015 | 116 | TACE (64 patients) TACE+PVE (52 patients) | Type I, II, III (according to Shi et al) | 27.7 mo | 60.9% 80.7% | 41% 59% | 25% 36.5% | 0% 11.5% |
First author, year | Patients (patients) | Treatment | PVTT Class (Vp) | Response rate | Survival rate(yr) | Mean survival time(mo) |
Tazawa, 2001 | 24 | RT (50 Gy)+TACE | Vp3,4 | 50% | NA | 9.7 mo |
Yamada, 2001 | 8 | RT (30 Gy) | Vp3 | 37.5% | NA | NA |
Ishikura, 2002 | 20 | TACE+RT (50 Gy) | Vp3 | 50% | 25% (1-yr) | 5.3 mo |
Yamada K, 2003 | 19 | TACE and 3D-RT (30Gy) | Vp3 | 57.9% | 40.6%(1-yr), 10.2% (2-yr) | 7 mo |
Nakagawa, 2005 | 52 | 3D-CRT (39-60 Gy) | Vp2,3,4 | NA | 5.1% (5-yr) | NA |
Kim DY, 2005 | 59 | 3D-CRT (39-70.2 Gy) | Vp3,4 | 45.8% | 20.7% (2-yr) | 10.7 mo |
Hata, 2005 | 12 | Proton-beam therapy (50-72 Gy) | Vp3,4 | 100% | 88% (2-yr) 58% (5-yr) | 27 mo |
Lin CS, 2006 | 43 | 3D-CRT (21patients) Conventional Rtp (22 patients) | Vp3,4 | 83% 75% | NA NA | 6.7 mo 6.0 mo |
Hsu WC, 2006 | 53 | 3D-CRT+thalidomide | Vp3,4 | 50% | 84.8% (6mo), 60.0% (1-yr), 44.6% (2-yr) | 24.0 mo |
Nakazawa, 2007 | 32 | RT | Vp3-4, Vv2-3 | 48% | 38.0% (1-yr), 20.7% (2-yr) | 10.0 mo |
Toya, 2007 | 38 | 3D-CRT (23.4-59.5 Gy) | Vp NA | 44.7% | 39.4% (1-yr) | 9.6 mo (OS) |
Shirai, 2009 | 26 | 3D-CRT using SPECT | Vp3,4 | 30.7% | 30% (2-yr) | 10.3 mo |
Kang, 2013 | 101 | RT+TACE TACE+RT | Vp NA | 70.3% | A) 58.8% (1-yr), 29.4% (2-yr) B) 54.1% (1-yr), 27.0% (2-yr) | 17 mo 15 mo |
Nakazawa, 2014 | 97 | 3D-CRT (30-56 Gy) | Vp3,4 | 45% | NA | 10.9 mo |
Lee, 2014 | 46 | 3D-CRT (35-60 Gy) | Vp3,4 | 32.6% | 66.8% (1-yr) | NA |
First author, year | Patients (patients) | PVTT Class (Vp) | Mortality | 5-yr survival rate | Median survival time (mo) |
Yamaoka, 1992 | 29 | 3-4 | 11% | 11.6% (3-yr) | NA |
Ikai, 1998 | 26 | 3 4 | NA | 11% 4% | NA |
Ohkubo, 2000 | 47 | 2-3-4 | 0% | 23.9% | 14 mo |
Wu, 2000 | 97 15 | 1-2-3 4 | 3.1% 0% | 28.5% 26.4% | NA NA |
Poon, 2003 | 20 | 3-4, Vv2 | 5.7% | 13.3% | 6.0 mo |
Ikai et al, 2004 (21,711 patients treated from 1989 to 1999) | 17,867 1609 672 679 | 0 1 2 3-4 | NA | 56.5% 34.4% 27.0% 17.3% | NA |
Pawlik, 2005 | 102 | 3, Vv 2-3 | 5.9% | 10% | 11 mo |
Ikai, 2006 | 78 | 3-4 | 3.8% | 10.9% | 8.9 mo |
Chen, 2007 | 286 152 | 1-3 4 | NA 2.6% | 18.1% 0% | 10.1 mo |
Le Treut, 2006 | 26 | 3-4, Vv2-3 | 11.5% | 13% | 9.0 mo |
Zhou, 2006 | 381 | 2-3-4 | NA | 12% | NA |
Shi, 2011 | 144 189 86 22 | 1 2 3 4 | NA | 26.7% (3-yr) 16.9% (3-yr) 3.7% (3-yr) 0% (3-yr) | NA |
Inoue et al. 2009 | 20 | 4 | 0% | 39.0% | NA |
Ban, 2009 | 45 | 3 4 | 0% 0% | 41.8% 20.9 | 20.0 mo |
Kondo, 2009 | 5 | 4 | 0% | 0% | 8.0 mo |
Ikai et al 2010 (25,066 patients treated from 1994 to 2005) | 20,195 1978 820 1,021 | 0 1 2 3-4 | NA | 59.0% 39.1% 23.3% 18.3% | NA |
Shi, 2010 | 169 78 | 3 4 | 0.6% 0% | 17.7% (3-yr) 3.6% (3-yr) | 15.0 mo 10.0 mo |
Wang, 2013 | 25 | Vv3 | 0% | 13.5% | NA |
Chok, 2013 | 88 | 1-2-3-4 | 3.3% | 11.2-14.3% | NA |
Pesi, 2015 | 15 5 21 8 3 | 1 2 3 Vv2 Vv3 | NA | 53.3% 30.1% 20.0% NA NA | NA |
Xu, 2015 | 16 40 | A B | 100% NA | 0% 5.2% | NA |
Kokudo, 2016 | 1772 1475 1942 1285 | 1 2 3 4 | NA | NA | 2.67 yr 1.51 yr 0.78 yr 0.50 yr |
Kudo, 2016 | 1908 714 852 | 1 2 3-4 | NA | 48.2% 29.2% 25.05 | NA |
- Citation: Cerrito L, Annicchiarico BE, Iezzi R, Gasbarrini A, Pompili M, Ponziani FR. Treatment of hepatocellular carcinoma in patients with portal vein tumor thrombosis: Beyond the known frontiers. World J Gastroenterol 2019; 25(31): 4360-4382
- URL: https://www.wjgnet.com/1007-9327/full/v25/i31/4360.htm
- DOI: https://dx.doi.org/10.3748/wjg.v25.i31.4360